1. Home
  2. ANVS vs MYO Comparison

ANVS vs MYO Comparison

Compare ANVS & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

N/A

Current Price

$1.82

Market Cap

76.6M

Sector

Health Care

ML Signal

N/A

Logo Myomo Inc.

MYO

Myomo Inc.

N/A

Current Price

$1.73

Market Cap

68.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ANVS
MYO
Founded
2008
2004
Country
United States
United States
Employees
N/A
195
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.6M
68.9M
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
ANVS
MYO
Price
$1.82
$1.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$13.50
$7.67
AVG Volume (30 Days)
590.2K
646.3K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
39.39
N/A
EPS
N/A
N/A
Revenue
N/A
$1,000,000,000.00
Revenue This Year
N/A
$9.10
Revenue Next Year
N/A
$13.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
40814.79
52 Week Low
$1.54
$0.61
52 Week High
$5.50
$1.89

Technical Indicators

Market Signals
Indicator
ANVS
MYO
Relative Strength Index (RSI) 48.27 65.54
Support Level $1.73 $0.69
Resistance Level $2.02 N/A
Average True Range (ATR) 0.10 0.18
MACD -0.00 0.05
Stochastic Oscillator 25.39 83.82

Price Performance

Historical Comparison
ANVS
MYO

About ANVS Annovis Bio Inc.

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

About MYO Myomo Inc.

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.

Share on Social Networks: